You just read:

Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference

News provided by

Blueprint Medicines

Aug 21, 2017, 16:30 ET